Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414953 | A Phase Ib Study of HS-10504 Combined Therapy in NSCLC | not yet recruiting | Phase 1 | 400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 17, 2026 |
| clinicaltrials |
| NCT07218367 | Phase I Trial of pH Resections of GBM at VA | not yet recruiting | Phase 1 | 12 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | not yet recruiting | Phase 1 / Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | not yet recruiting | Phase 1 | 102 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07391566 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 99 | Luye Pharma Group Ltd.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07391644 | A Study of JSKN027 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 250 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06203821 | Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer | not yet recruiting | Phase 1 | 25 | Aram HezelOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | not yet recruiting | Phase 1 | 8 | Jennifer LeddonOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07383233 | CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma | not yet recruiting | Phase 1 | 18 | Qi dengOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | not yet recruiting | Phase 1 / Phase 2 | 89 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07335380 | Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 30 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07370506 | Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 36 | Tanta UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia(AML CAR-T) | not yet recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07367685 | Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma | not yet recruiting | Phase 1 | 6 | The Second Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07363369 | Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07364422 | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Onconic Therapeutics Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07351565 | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer(CPPGPTCLC) | not yet recruiting | Phase 1 | 22 | Chang ChenOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07348107 | ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.(ATARI-PDAC) | not yet recruiting | Phase 1 | 10 | Daniel BreadnerOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07333469 | A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Hanx Biopharmaceuticals (Wuhan) Co., Ltd.INDUSTRY | 0 | Jan 13, 2026 | clinicaltrials |
| NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL(XP-006) | not yet recruiting | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 60 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07333573 | A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07333820 | Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201 | not yet recruiting | Phase 1 | 18 | Yonsei UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor(GABRIEL) | not yet recruiting | Phase 1 | 15 | Sarah RumlerOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT07316920 | A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Phase 1 | 19 | YANRU WANGOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC | not yet recruiting | Phase 1 | 10 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07320222 | CARE-Melanoma Trial(CARE-Melanoma) | not yet recruiting | Phase 1 | 30 | McMaster UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT07316907 | A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies | not yet recruiting | Phase 1 | 12 | YANRU WANGOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)(BaseCAR-01) | not yet recruiting | Phase 1 | 12 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 219 | TYK Medicines, IncINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07291050 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07269158 | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 1 / Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07027423 | BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas | not yet recruiting | Phase 1 | 32 | University Health Network, TorontoOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07244393 | Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 30 | Cellbion Co., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07196384 | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW(GLOW) | not yet recruiting | Phase 1 | 15 | University Medical Center GroningenOTHER | 0 | Nov 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials